跳至主要内容
临床试验/CTRI/2025/09/094739
CTRI/2025/09/094739尚未招募4 期

Topical Zinc sulphate for chemotherapy-induced dysgeusia among breast cancer patients receiving Chemotherapy:- Pilot study patients receiving Chemotherapy- Pilot study

Dr Mirunalini R1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年12月1日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
20
试验地点
1
主要终点
Change in taste perception by taste acuity method

研究概览

简要总结

The study is yet to start the recruitment.

During the second cycle, the patient will be enrolled for the study. Baseline CITAS and taste assessment**using taste strip (details given below) will be done

The participant will be advised to take the entire solution in the mouth and move it around

without swallowing it. Then post procedure CITAS and taste assessment using taste strip will be done to

evaluate immediate effect.

To evaluate the sustained effect of zinc sulfate by swish and spit (Z-SAS), the study intervention will be

given three times a day before each meal for 2 weeks and will be tested for the taste perception using

CITAS and taste strip testing method during the third cycle.

Quality of life assessment The Quality of life score will be assessed by Cancer Institute quality of life scores

at the baseline and at the end of study.

Adverse event monitoring: The frequency of Adverse events that are possibly due to zinc sulphate will be

studied. All patients will be monitored for adverse events during the study period (CTCAE version 5.0)

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 90.00 Year(s)(—)
性别
Female

入选标准

  • patients with breast cancer planned for curative intent therapy (neoadjuvant or adjuvant ) with epirubicin and cyclophosphamide agents during first cycle.

排除标准

  • Patients who had received zinc preparations within the last two weeks of enrolment
  • Known hypersensitivity to the drug
  • Known psychiatric disorder
  • Regular alcohol intake (3 or more drinks equivalent of 45 ml of liquor per week).

结局指标

主要结局

Change in taste perception by taste acuity method

时间窗: Baseline and two weeks

Change in CiTAS score

时间窗: Baseline and two weeks

次要结局

  • Adverse drug reaction to Topical Zinc(Over two weeks)

研究者

发起方
Dr Mirunalini R
申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Dr Mirunalini R

JIPMER, Puducherry

研究点 (1)

Loading locations...

相似试验